insulin sensitivity oxidative stress
Conditions
Interventions
Patients will receive from the moment of admission oral administration of
taurine (3g/day or 6g/day, depending on results of the dose finding study) or
placebo.
Sponsors
Medisch Centrum Alkmaar
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: For part 1 and 2:;age >75 years hip fracture with primary indication for surgery having obtained his/her informed consent;For part 3:;age >60 years hip artrosis with primary indication for total hip replacement having obtained his/her informed consent
Exclusion criteria
Exclusion criteria: participating in another clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is the morbidity, which is related to the mortality rate. The aim is to achieve an 50% reduction in the excessive mortality one year postoperative. Morbidity and mortality will be measured during the hospital stay, at three, six, nine and twelve months postoperative. | — |
Secondary
| Measure | Time frame |
|---|---|
| - postoperative insulin resistance - antioxidant/oxidant parameters - postoperative delirium | — |
Countries
Netherlands
Outcome results
None listed